| 商品名称 | Betaferon |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Multiple Sclerosis |
| 通用名/非专利名称 | interferon beta-1b |
| 活性成分 | interferon beta-1b |
| 产品号 | EMEA/H/C/000081 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | L03AB08 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 1995/11/30 |
| 上市许可开发者/申请人/持有人 | Bayer AG |
| 人用药物治疗学分组 | Immunostimulants |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 1995/07/12 |
| 欧盟委员会决定日期 | 2023/11/23 |
| 修订号 | 36 |
| 治疗适应症 | Betaferon is indicated for the treatment of patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis; patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years; patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2017/07/28 |
| 最后更新日期 | 2023/11/23 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon |